| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $12,983,320 | 1 | 100 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 0 | $0 | 1 | $12.98M | $-12.98M |
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Over the last 12 months, insiders at ArriVent BioPharma, Inc. Common Stock have bought $0 and sold $12.98M worth of ArriVent BioPharma, Inc. Common Stock stock.
On average, over the past 5 years, insiders at ArriVent BioPharma, Inc. Common Stock have bought $26M and sold $12.98M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 555,555 shares for transaction amount of $10M was made by HILLHOUSE INVESTMENT MANAGEMENT, LTD. (10 percent owner) on 2024‑01‑30.
| 2025-12-10 | Sale | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 555,555 1.6309% | $23.37 | $12.98M | -6.60% | |
| 2024-01-30 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 555,555 1.2562% | $18.00 | $10M | 0.00% | ||
| 2024-01-30 | HEALY JAMES | director | 444,444 1.0049% | $18.00 | $8M | 0.00% | ||
| 2024-01-30 | ORBIMED ADVISORS LLC | 222,222 0.5025% | $18.00 | $4M | 0.00% | |||
| 2024-01-30 | GORDON CARL L | 222,222 0.5025% | $18.00 | $4M | 0.00% |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | 3929117 8.8891% | $116.46M | 1 | 1 | 0% |
| HEALY JAMES | director | 1696752 3.8387% | $50.29M | 1 | 0 | 0% |
| ORBIMED ADVISORS LLC | 1513664 3.4245% | $44.87M | 1 | 0 | 0% | |
| GORDON CARL L | 1513664 3.4245% | $44.87M | 1 | 0 | 0% |
$8,217,280 | 112 | 46.33% | $1.44B | |
$607,159,124 | 92 | 3.55% | $1.2B | |
$100,473,344 | 83 | 9.53% | $1.41B | |
$14,874,415 | 78 | 37.43% | $1.18B | |
$150,336,897 | 29 | -5.97% | $1.22B | |
$104,199,091 | 28 | 16.42% | $1.16B | |
$121,322,364 | 24 | -6.74% | $1.25B | |
$169,638,586 | 22 | 30.82% | $1.28B | |
$276,750,010 | 16 | -7.95% | $1.29B | |
$73,814,940 | 15 | -4.77% | $1.26B | |
$48,220,484 | 14 | 2.13% | $1.29B | |
$144,557,026 | 13 | 0.49% | $1.47B | |
$50,004,159 | 12 | 75.04% | $1.53B | |
$117,959,652 | 9 | -12.47% | $1.32B | |
$130,038,539 | 8 | 26.82% | $1.41B | |
ArriVent BioPharma, Inc. Common Stock (AVBP) | $25,999,974 | 4 | 0.00% | $1.31B |
$162,238 | 3 | 144.37% | $1.45B | |
$33,624,000 | 2 | -50.37% | $1.32B | |
$152,517 | 2 | 177.13% | $1.54B |
| Increased Positions | 71 | +62.83% | 5M | +12.23% |
| Decreased Positions | 49 | -43.36% | 3M | -8.25% |
| New Positions | 31 | New | 3M | New |
| Sold Out Positions | 15 | Sold Out | 1M | Sold Out |
| Total Postitions | 135 | +19.47% | 40M | +3.98% |